What Is in the Literature

Area of Science:

• Neurology
• Genetics
• Clinical Trials

Background:

• Amyotrophic lateral sclerosis (ALS) pathophysiology remains largely unknown.
• Over 22 genes are linked to ALS, but underlying mechanisms are unclear.
• Current FDA-approved treatments for ALS are limited to riluzole and edaravone.

Purpose of the Study:

• To review current literature on amyotrophic lateral sclerosis (ALS).
• To discuss ongoing drug and stem cell trials for ALS.
• To highlight advancements in ALS diagnosis and management.

Main Methods:

• Literature review of recent findings in amyotrophic lateral sclerosis (ALS).
• Analysis of ongoing phase 2 and phase 3 clinical trials.
• Discussion of diagnostic and management strategies.

Main Results:

• No new drugs beyond riluzole and edaravone have succeeded in phase 3 trials.
• Results from a phase 2 stem cell trial are presented.
• Efforts are underway to enhance the sensitivity of clinical trials.

Conclusions:

• Understanding ALS pathophysiology is critical for developing effective treatments.
• Stem cell therapies show promise and warrant further investigation.
• Improved diagnostic and management approaches are essential for ALS patient care.